Valuation
- Market cap
- 5,268,000
- Revenue TTM
- $2,910,000
- Net income TTM
- $-27,060,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -929.90%
- Debt to equity
- 0.04
Trading
- Volume
- 25,368
- Avg volume
- 1,059,542
- Day's range
- $0.16 – $0.17
- Shares out
- 35,119,000
- Stochastic %K
- 44%
- Beta
- 0.48
- Analysts
- —
- Price target
- —
Company profile
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VX...
Show more
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026. OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 425 635 7700
- Website
- https://osr-holdings.com
- Address
- 10900 NE 4th Street, Suite 2300, Bellevue, United States
Latest news
No headlines yet.
